Grace Therapeutics, Inc. SEC filings GRCE
Grace Therapeutics, Inc. has 594 filings in SEC EDGAR's recent list, going back to Sep 2, 2008. Its latest annual report, Form 10-K, was filed on Jun 18, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 18, 2026 (shareholder vote results). The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-3 | Shelf registration | Aug 24, 2026 | — |
| S-3 | Shelf registration | Mar 10, 2025 | — |
| S-8 | Employee stock plan registration | Oct 8, 2024 | — |
| S-8 POS | Filing | Oct 8, 2024 | — |
| S-8 POS | Filing | Oct 8, 2024 | — |
| S-8 POS | Filing | Oct 8, 2024 | — |
| POS AM | Filing | Oct 8, 2024 | — |
| POS AM | Filing | Oct 8, 2024 | — |
| 424B3 | Prospectus | Aug 7, 2024 | — |
| S-4/A | Filing | Jul 31, 2024 | — |
| S-4 | Registration for a merger or exchange | Jun 27, 2024 | — |
| 424B3 | Prospectus | Oct 16, 2023 | — |
| S-3 | Shelf registration | Oct 6, 2023 | — |
| S-8 | Employee stock plan registration | Aug 25, 2023 | — |
| 424B3 | Prospectus | Jun 23, 2022 | — |
| 424B5 | Prospectus supplement | Nov 10, 2021 | — |
| 424B3 | Prospectus | Jul 15, 2021 | — |
| S-4/A | Filing | Jul 13, 2021 | — |
| S-4 | Registration for a merger or exchange | Jul 1, 2021 | — |
| 424B5 | Prospectus supplement | Jul 7, 2020 | — |
| S-3 | Shelf registration | Jun 29, 2020 | — |
| F-3 | Shelf registration (foreign issuer) | Aug 7, 2019 | — |
| POS AM | Filing | Jul 15, 2019 | — |
| 424B5 | Prospectus supplement | Feb 14, 2019 | — |
| POS AM | Filing | Oct 12, 2018 | — |
| 424B5 | Prospectus supplement | Oct 5, 2018 | — |
| 424B5 | Prospectus supplement | Oct 3, 2018 | — |
| S-8 | Employee stock plan registration | Sep 21, 2018 | — |
| POS AM | Filing | Sep 21, 2018 | — |
| F-3 | Shelf registration (foreign issuer) | Mar 6, 2018 | — |
| 424B3 | Prospectus | Feb 15, 2018 | — |
| 424B3 | Prospectus | Jan 18, 2018 | — |
| 424B4 | Prospectus | Dec 22, 2017 | — |
| F-1/A | Filing | Dec 19, 2017 | — |
| F-1/A | Filing | Dec 18, 2017 | — |
| F-1/A | Filing | Dec 15, 2017 | — |
| F-1/A | Filing | Nov 29, 2017 | — |
| FWP | Free writing prospectus | Nov 24, 2017 | — |
| F-1/A | Filing | Nov 24, 2017 | — |
| F-1/A | Filing | Nov 16, 2017 | — |
| F-1 | Registration statement (foreign issuer) | Sep 29, 2017 | — |
| F-X | Form f-x | Oct 25, 2013 | — |
| F-10 | Form f-10 | Oct 25, 2013 | — |
| S-8 | Employee stock plan registration | Sep 25, 2013 | — |
| F-X | Form f-x | Jul 20, 2012 | — |
| F-X | Form f-x | Sep 2, 2008 | — |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GRCE (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1444192
- Former names
- Acasti Pharma Inc. (until Oct 25, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.